Published in Cancer Res on April 15, 1990
Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest (1992) 2.08
HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 1.71
Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer (2002) 1.27
Interleukin 2 therapy in cancer: identification of responders. Br J Cancer (1992) 1.00
Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clin Exp Immunol (1994) 0.92
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. Br J Cancer (1992) 0.89
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br J Cancer (1992) 0.81
In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer (1994) 0.80
Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. Br J Cancer (1992) 0.79
Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression. Br J Cancer (1993) 0.79
Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol (1994) 0.78
Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. Clin Exp Immunol (1994) 0.75
SOR: project methodology. Br J Cancer (2001) 5.24
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Induction of tumor necrosis factor alpha expression in human T lymphocytes following ionizing gamma irradiation. J Interferon Cytokine Res (1996) 4.88
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood (1998) 2.93
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res (1992) 2.64
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol (2000) 2.20
Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol (2009) 2.12
Case report: a preterm infant with an extradural myxopapillary ependymoma component of a teratoma and high levels of alpha-fetoprotein. Pediatr Hematol Oncol (1999) 2.01
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98
Quality assessment of genetic markers used for therapy stratification. J Clin Oncol (2003) 1.92
A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants. J Immunol (1986) 1.88
[The value of anesthesia consultation in relation to the single preanesthetic visit]. Ann Fr Anesth Reanim (1999) 1.87
Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol (1985) 1.86
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77
International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol (1999) 1.76
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer (1997) 1.70
Long-term survival of HeLa tumours in mice treated with antilymphocyte serum. Br J Cancer (1973) 1.69
Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate? Br Med J (Clin Res Ed) (1982) 1.69
Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet (1986) 1.68
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol (2004) 1.65
Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22)(q24;q12). Cancer Genet Cytogenet (1984) 1.65
Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem-Cell Transplantation in Malignancies: Lyon, France, June 4-6, 1993. J Clin Oncol (1994) 1.63
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood (1993) 1.52
Impact of a clinical guidelines program for breast and colon cancer in a French cancer center. JAMA (1997) 1.50
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood (1998) 1.49
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol (1991) 1.49
The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol (1984) 1.46
Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res (1996) 1.45
High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol (2001) 1.45
The mechanism of inhibition of human IL 2 production. J Immunol (1982) 1.44
[Can hydroxyethylamidon be used during intensive care of brain-dead organ donors?]. Ann Fr Anesth Reanim (1994) 1.40
Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene (2007) 1.40
Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother (1990) 1.37
Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol (2004) 1.37
Pleural infection caused by Legionella anisa. J Clin Microbiol (1989) 1.36
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol (2011) 1.34
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol (1998) 1.31
[Permanent mechanical ventilation at home via a tracheotomy in chronic respiratory insufficiency]. Rev Fr Mal Respir (1983) 1.29
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol (1996) 1.27
Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol (1986) 1.26
The effect of sex hormones on peripheral immunity in patients with advanced breast cancer. Clin Oncol (1978) 1.26
Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow. Br J Cancer (1986) 1.25
A controlled "before-after" study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. Br J Cancer (2002) 1.24
Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol (2001) 1.23
Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet (1984) 1.22
Neuroectoderm-associated antigens on Ewing's sarcoma cell lines. Cancer Res (1987) 1.21
Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer (2001) 1.18
High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. J Clin Oncol (1987) 1.16
A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res (2001) 1.15
The effect of sex hormones on the growth of HeLa tumour nodules in male and female mice. Br J Cancer (1975) 1.15
Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer (2011) 1.15
Tumor-specific loss of 11p15.5 alleles in del11p13 Wilms tumor and in familial adrenocortical carcinoma. Proc Natl Acad Sci U S A (1989) 1.14
IL-15 enhances immune functions during HIV infection. J Immunol (1997) 1.13
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene (2012) 1.13
In vitro processing of human tumor necrosis factor-alpha. J Biol Chem (1995) 1.12
Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia (2006) 1.11
Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res (2001) 1.10
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin. J Natl Cancer Inst (1984) 1.10
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer (2001) 1.10
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer (2011) 1.09
Does nephroblastomatosis influence the natural history and relapse rate in Wilms' tumour? A single centre experience over 11 years. Eur J Cancer (2001) 1.08
Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer (1998) 1.07
Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol (1998) 1.07
Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol (1990) 1.06
The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene (2011) 1.06
Subcutaneous growth of human tumours in mice. Nature (1973) 1.05
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer (2003) 1.05
Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. J Clin Invest (1987) 1.04
Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer (2005) 1.04
IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis. J Biol Chem (1997) 1.03
Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood (1998) 1.02
A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol (1989) 1.02
Burkitt-type lymphoma in France among non-Hodgkin malignant lymphomas in Caucasian children. Br J Cancer (1982) 1.01
Regional assignment of the ADA locus on 20q13.2 leads to qter by gene dosage studies. Cytogenet Cell Genet (1980) 1.01
[Methodology of the development of diagnostic and therapeutic standards, options and recommendations in oncology]. Bull Cancer (1995) 1.01
Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant (1989) 1.01
Differential effect of anti-beta 2-microglobulin on IL 2 production and IL 2 receptor expression in the primary mixed lymphocyte culture reaction. J Immunol (1985) 1.01
Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol (1996) 1.01
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines. Oncogene (2011) 1.00
Interleukin 2 therapy in cancer: identification of responders. Br J Cancer (1992) 1.00
Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer (2001) 0.98
Variant translocation in a non endemic case of Burkitt's lymphoma: t (8;22) in an Epstein--Barr virus negative tumour and in a derived cell line. Eur J Cancer (1981) 0.98
Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone marrow samples. Eur J Pediatr (1988) 0.98
Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. J Biol Chem (1997) 0.98
A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique. J Clin Oncol (1987) 0.98